

# **Structural Basis of Species Differences between Rat and Human CYP1A1s in Metabolism of Polychlorinated Biphenyls**



**Hideyuki Inui**

**Research Center for Environmental Genomics,  
Kobe University**

**14 Feb. 2014**

# Cytochrome P450 (CYP) monooxygenases

- Monooxygenase reaction
- Endogenous and exogenous compounds as a substrate
- Broad and overlapping substrate specificity



**Critical roles in drug metabolism in mammals**

# Dioxin-like toxicity of PCBs

Persistent organic pollutants (POPs)

Persistency in the environment

Wide distribution

Bioaccumulation through the food chain



Adverse effects to wildlife and human health by dioxin-like toxicity such as

Carcinogenicity

Hepatotoxicity

Teratogenicity

Mutagenicity

Congener	TEF
<b>3,3',4,4'-TeCB (#77)</b>	<b>0.0001</b>
3,4,4',5-TeCB (#81)	0.0003
<b>3,3',4,4',5-PeCB (#126)</b>	<b>0.1</b>
3,3',4,4',5,5'-HxCB (#169)	0.03
2',3,4,4',5-PeCB (#123)	0.00003
2,3',4,4',5-PeCB (#118)	0.00003
2,3,3',4,4'-PeCB (#105)	0.00003
2,3,4,4',5-PeCB (#114)	0.00003
2,3',4,4',5,5'-HxCB (#167)	0.00003
2,3,3',4,4',5-HxCB (#156)	0.00003
2,3,3',4,4',5'-HxCB (#157)	0.00003
2,3,3',4,4',5,5'-HpCB (#189)	0.00003

TEF; Toxic equivalency factor

WHO, 2005

# Metabolism of PCBs in microsomal fractions of rat and human CYP1A1s

## Reaction condition

40pmol Microsomal fraction containing rat or human CYP1A1

0.5mM NADPH

5mM G6P

1U G6PDH

3.3mM MgCl<sub>2</sub>




100mM Potassium phosphate buffer

~2ppm CB126, CB77

0.5ml

37°C, 2-hour incubation


1. Addition of NADPH to start reaction
2. A reaction mixture without NADPH is used as a control.
3. Addition of <sup>13</sup>C-OH-PCBs after stopping a reaction
4. Extraction of metabolites with hexane
5. Dryness and methylation
6. Quantification and identification of metabolites with high resolution GC/MS






# Homology modeling of rat and human CYP1A1s

Rat CYP1A1




Human CYP1A1



F316 is conflicted with Y263, and then flipped to the side of substrate binding pocket. It results in a small volume of substrate binding pocket in rat CYP1A1.

# Structures of amino acid residues consisting of a substrate binding pocket in mammalian CYP1A1s

Number (rat)	Human	Rat	Dog	Golden hamster	Guinea pig	Monkey	Mouse	Rabbit
<b>A120</b>	<chem>OC</chem> Ser	<chem>CC</chem> <b>Ala</b>	<chem>CC(O)C</chem> Thr	<chem>CC(O)C</chem> Thr	<chem>OC</chem> Ser	<chem>OC</chem> Ser	<chem>CC(O)C</chem> Thr	<chem>CC(O)C</chem> Thr
<b>Y263</b>	<chem>Oc1ccc(C)cc1</chem> Tyr	<chem>Oc1ccc(C)cc1</chem> Tyr	<chem>Oc1ccc(C)cc1</chem> Tyr	<chem>Oc1ccc(C)cc1</chem> Tyr	<chem>OC</chem> Ser	<chem>C1=CN=C(N)N=C1</chem> His	<chem>Oc1ccc(C)cc1</chem> Tyr	<chem>Oc1ccc(C)cc1</chem> Tyr
<b>F316</b>	<chem>CC(C)C</chem> Leu	<chem>c1ccccc1</chem> <b>Phe</b>	<chem>CC(C)C</chem> Leu	<chem>CC(C)C</chem> Leu	<chem>CC(C)C</chem> Leu	<chem>CC(C)C</chem> Leu	<chem>CC(C)C</chem> Leu	<chem>CC(C)C</chem> Leu





The **Y263** causing the conflict is well conserved. Both residues **A120** and **F316**, seen in rat CYP1A1, are rare in other well-studied mammalian CYP1A1s.

These findings suggest that the cavity shape and catalytic activity of rat CYP1A1 may be unique among experimental animals.





# Docking model of **CB126** with rat and human CYP1A1s

## Orientation



CB126 is **more stable** in the cavity of rat CYP1A1 than that of human CYP1A1.


## Distance from the iron of the heme ( $\text{Fe-C4} \leq 5 \text{ \AA}$ )



CB126 is **more accessible** to the heme of rat CYP1A1 than that of human CYP1A1.



# Species differences on metabolism of PCBs between human and rat CYP1A1s



The rat is **not always** a suitable animal for estimating effects in humans, such as dioxin toxicity and endocrine disruption, if they are metabolized by CYP1A1.